中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    NASH Cancer Lipid Metabolism and Oral Checkpoint Inhibitors Viral Hepatitis/HIV/AIDS
  • Pipeline & Products
    Pipeline Products Clinical Trials
  • Partnership
  • Investors
    Financials & Filing Presentation Materials
  • News
  • Careers
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • First Subject Dosed with Gannex’s FXR Agonist ASC42 in a U.S. Phase I Trial

    2020-12-28

  • Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial

    2020-12-22

  • Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42,an FXR Agonist

    2020-12-14

  • Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study

    2020-12-03

  • Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer

    2020-11-30

 
  • 1
  • 2
  • 3
  • 4
  •  
  • »
    • © 2018 Ascletis Pharma Inc.
    • 浙公网安备 33010802003344号
    • All Rights Reserved
    • 浙ICP备 11050387号

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备 11050387号